Background Background: Despite regulatory approval and advancements of immune-based interventions over the last decade, significant obstacles remain to be overcome before the full potential of immunotherapy can be realized to improve outcomes for cancer patients [1,3]. The NCI Cancer Moonshot Immuno-Oncology Translational Network (IOTN) was established in 2018 with the overarching goal of improving the efficacy, durability, and safety of immunotherapy across the spectrum of human cancers, as well as developing immunoprevention approaches that will prevent cancers before they occur.1,2
Methods The IOTN consortium, consisting of 29 research project awards spanning 33 institutions, conducts translational research focused on four thematic areas: Immunotherapy, Immuno-Engineering to improve immuno-therapy (i3), Mitigating immune related adverse events (irAE) and Immuno-Prevention.2, 3 At each stage of the IOTN's translational studies, the Data Management Resource Sharing Center (DMRC) serves as an administrative and analytic hub, focusing on lowering barriers for access to analytic expertise, improving network productivity, maintaining a high standard for data collection and management, and fostering a collaborative and supportive research community.
Results The DMRC has developed centralized infrastructures to enhance the IOTN’s research output, including a collection of publicly accessible and scalable resource sharing catalogs for Data, Model, Software and Clinical Trials.4 In addition to supporting intra-network collaboration, the DMRC engaged cross-moonshot communication by hosting and coordinating a number of meetings and workshops, including the inaugural Cancer Moonshot Collaborative Meeting and monthly NCI Cancer Moonshot Seminar Series.5, 6 The DMRC in collaboration with SITC has organized the highly popular SITC-NCI webinar series on “Computational Science in Immuno-Oncology”, fostering collaboration, communication and outreach to the broader communities.7
Conclusions The IOTN's consortium structure, strengthened by the DMRC's centralized management, analytical, and data integration supports, has facilitated effective intra- and inter-moonshot communication and enabled collaborative translational studies.
Acknowledgements This work was supported by IOTN Moonshot grant U24CA232979-01
Jacks T, Jaffee E and Singer D. Blue Ribbon Panel Co-Chairs (2016) Cancer Moonshot Blue Ribbon Panel Report. National Cancer Institute, Bethesda, MD.
Adult Immunotherapy Network Fact Sheet [https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/implementation/adult-immunotherapy-network/fact-sheet.pdf]
Annapragada A, Sikora A, Bollard C, et al. Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. J Immunother Cancer 2020;8:e00079.
Immuno-Oncology Translational Network. IOTN Resource Sharing Catalogs. 2022. Available from: https://www.iotnmoonshot.org/en/resources/all-resources/.
National Cancer Institute. Cancer Moonshot Workshop Highlights Advances – National Cancer Institute 2020. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2020/cancer-moonshot-nci-workshop-advances-collaboration.
National Cancer Institute. Cancer MoonshotSM Seminar Series [online workshop series], September 24, 2020-May 26, 2022: National Cancer Institute; 2021. Available from: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/seminar-series.
18. Society for Immunotherapy of Cancer. SITC-NCI Computational Immuno-oncology Webinar Series [online workshop series], May 11, 2021-December 17, 2022: Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI); 2021 Available from: https://www.sitcancer.org/education/computational.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.